Skip to content

Correlation of Toxins With Gastrointestinal (GI) and Overall Health

Association of Presenting Symptoms and Diagnosis, With Urinary Mycotoxins, Metals, Polyfluorinated Alkyl Substance (PFAS) and Environmental Toxins - A Prospective Study in an Urban Gastroenterology Practice

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06278311
Enrollment
250
Registered
2024-02-26
Start date
2025-02-28
Completion date
2026-01-31
Last updated
2024-11-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastrointestinal Diseases

Keywords

Gastrointestinal symptoms, Toxins, Environmental Toxins, Heavy metals, PFAS, Mycotoxins

Brief summary

The goal of this observational study is to evaluate the levels of urinary environmental toxins, heavy metals, PFAS and mycotoxins with gastrointestinal (GI) and overall health.

Detailed description

This study aims to use urine samples to understand the effect of toxins such as environmental toxins, heavy metals, PFAS and mycotoxins on GI and overall health. Urine samples will be tested using mass-spectroscopy-based techniques. A 'total toxicity score' will be calculated based on the urine analysis of toxins. A 'symptoms score' will be determined using the 'Symptom History' form which will be used to assess the patient's GI conditions. Additionally, a 'diagnosis score' will be calculated from the diagnosis generated in the electronic medical record (EMR). The determined 'total toxicity score' will be correlated with the 'symptoms score' and the 'diagnosis score.' The observations from this study will help us understand the potential effect of environmental toxins, heavy metals, PFAS and mycotoxins on GI and overall health.

Interventions

None listed

Sponsors

Los Angeles Integrative Gastroenterology and Nutrition, Inc
CollaboratorUNKNOWN
Vibrant America Clinical Lab
Lead SponsorINDUSTRY

Study design

Observational model
CASE_CONTROL
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Patients suffering from gastrointestinal and/or other symptoms * Patients willing to provide urine samples * Patients willing to provide consent

Exclusion criteria

* Use of antibiotics 2 weeks prior to the study * Patients unwilling to consent

Design outcomes

Primary

MeasureTime frameDescription
Determination of the Total Toxicity score1 yearMass spectroscopy-based techniques will be used to test participants' urine samples for environmental toxins, heavy metals, PFAS, and mycotoxins. A 'total toxicity score' will be calculated based on the results obtained from the urine analysis of these toxins. The range for total toxicity score lies between 0 (none) to 232 (severe). Higher scores correspond with worse outcomes.
Determination of the Symptom score1 yearThe Symptom History Form is a 90-item questionnaire that will assess participants' digestive and non-digestive symptoms. The scale ranges from 0 (absent) to 1 (present). This form will help determine the 'symptom score.'
Determination of the Diagnosis score1 yearA diagnosis will be selected by the clinician as part of the medical evaluation during the follow-up patient visit. Diagnosis may be confirmed, suspected, or rule out all as part of a practitioner's clinical impressions. Each diagnosis score will be presented in the form of an International Classification of Diseases (ICD)-10 code. This will help determine the 'diagnosis score,' which applies only to the patient group.

Secondary

MeasureTime frameDescription
Determination of individual scores1 yearBased on the urine analysis, individual scores for environmental toxins, heavy metals, PFAS, and mycotoxins will be determined. The individual score ranges are as follows: Environmental toxins: 0 (none) to 78 (severe); Heavy metals: 0 (none) to 40 (severe); PFAS: 0 (none) to 52 (severe); Mycotoxins: 0 (none) to 62 (severe). In all cases, higher scores correspond with worse outcomes.

Countries

United States

Contacts

Primary ContactHari K Krishnamurthy, MS
hari@vibrantsci.com866-364-0963
Backup ContactDr. Farshid S Rahbar, MD
Research@laintegrativegi.com310-289-8000

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026